JP2009533410A - Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体 - Google Patents

Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体 Download PDF

Info

Publication number
JP2009533410A
JP2009533410A JP2009504834A JP2009504834A JP2009533410A JP 2009533410 A JP2009533410 A JP 2009533410A JP 2009504834 A JP2009504834 A JP 2009504834A JP 2009504834 A JP2009504834 A JP 2009504834A JP 2009533410 A JP2009533410 A JP 2009533410A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
compound
acceptable salt
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009504834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533410A5 (enExample
Inventor
マシュー・コリン・ソーア・ファイフ
ウィリアム・ガトレル
クリステル・マリー・ラサミソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2009533410A publication Critical patent/JP2009533410A/ja
Publication of JP2009533410A5 publication Critical patent/JP2009533410A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009504834A 2006-04-11 2007-04-11 Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体 Pending JP2009533410A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607196.3A GB0607196D0 (en) 2006-04-11 2006-04-11 G-protein coupled receptor agonists
PCT/GB2007/050190 WO2007116230A1 (en) 2006-04-11 2007-04-11 Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists

Publications (2)

Publication Number Publication Date
JP2009533410A true JP2009533410A (ja) 2009-09-17
JP2009533410A5 JP2009533410A5 (enExample) 2010-06-03

Family

ID=36539676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504834A Pending JP2009533410A (ja) 2006-04-11 2007-04-11 Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体

Country Status (13)

Country Link
US (1) US20090281076A1 (enExample)
EP (1) EP2010485B1 (enExample)
JP (1) JP2009533410A (enExample)
KR (1) KR20080109085A (enExample)
CN (1) CN101466667A (enExample)
AU (1) AU2007235674A1 (enExample)
BR (1) BRPI0709953A2 (enExample)
CA (1) CA2648687A1 (enExample)
GB (1) GB0607196D0 (enExample)
MX (1) MX2008012946A (enExample)
NO (1) NO20084364L (enExample)
NZ (1) NZ571962A (enExample)
WO (1) WO2007116230A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500659A (ja) * 2007-10-18 2011-01-06 プロシディオン・リミテッド アゼチジニルｇタンパク質共役受容体アゴニスト
JP2011500658A (ja) * 2007-10-18 2011-01-06 プロシディオン・リミテッド アゼチジニルｇタンパク質共役受容体アゴニスト
JP2013507366A (ja) * 2009-10-09 2013-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
JP2013538227A (ja) * 2010-09-17 2013-10-10 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン化合物およびその使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
MX2010003117A (es) 2007-09-20 2010-04-01 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
KR20100120689A (ko) * 2008-02-22 2010-11-16 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
US20110172244A1 (en) * 2008-02-22 2011-07-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EA018703B1 (ru) * 2008-04-07 2013-10-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
CA2730593A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8642583B2 (en) 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
WO2010059390A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Modulators of serotonin receptor
WO2010084512A1 (en) 2008-12-24 2010-07-29 Cadila Healthcare Limited Novel oxime derivatives
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
PH12013500671A1 (en) 2010-10-08 2018-04-11 Cadila Healthcare Ltd Novel gpr 119 agonists
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN104725355A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途
CN104725354A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构化合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007873A1 (en) * 1997-02-10 2001-07-12 Robert A. Volkmann 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
WO2003077907A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Azetidine derivatives as ccr-3 receptor antagonists
WO2004099144A1 (en) * 2003-05-09 2004-11-18 Astrazeneca Ab Chemical compounds
WO2005061489A1 (en) * 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2006034341A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US20060160786A1 (en) * 2005-01-20 2006-07-20 Pfizer Inc Substituted triazole derivatives as oxytocin antagonists
WO2006113704A2 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130309A (en) * 1991-04-12 1992-07-14 A. H. Robins Company, Incorporated Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007873A1 (en) * 1997-02-10 2001-07-12 Robert A. Volkmann 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
WO2003077907A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Azetidine derivatives as ccr-3 receptor antagonists
WO2004099144A1 (en) * 2003-05-09 2004-11-18 Astrazeneca Ab Chemical compounds
WO2005061489A1 (en) * 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2006034341A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US20060160786A1 (en) * 2005-01-20 2006-07-20 Pfizer Inc Substituted triazole derivatives as oxytocin antagonists
WO2006113704A2 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5009003724; ＲＯＬＬＡＮＤ: Ｊ．ＭＥＤ．ＣＨＥＭ． Ｖ４８　Ｎ２１, 2005, Ｐ６５６３-６５７４ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500659A (ja) * 2007-10-18 2011-01-06 プロシディオン・リミテッド アゼチジニルｇタンパク質共役受容体アゴニスト
JP2011500658A (ja) * 2007-10-18 2011-01-06 プロシディオン・リミテッド アゼチジニルｇタンパク質共役受容体アゴニスト
JP2013507366A (ja) * 2009-10-09 2013-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
JP2013538227A (ja) * 2010-09-17 2013-10-10 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン化合物およびその使用

Also Published As

Publication number Publication date
WO2007116230A1 (en) 2007-10-18
BRPI0709953A2 (pt) 2011-08-02
US20090281076A1 (en) 2009-11-12
MX2008012946A (es) 2008-11-28
KR20080109085A (ko) 2008-12-16
AU2007235674A1 (en) 2007-10-18
CN101466667A (zh) 2009-06-24
EP2010485A1 (en) 2009-01-07
CA2648687A1 (en) 2007-10-18
GB0607196D0 (en) 2006-05-17
NZ571962A (en) 2011-07-29
NO20084364L (no) 2008-10-31
WO2007116230A8 (en) 2007-12-27
EP2010485B1 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JP4916452B2 (ja) Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体
JP2011500659A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
JP5114395B2 (ja) Ｇｐｃｒアゴニスト
JP4958560B2 (ja) Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP2010514832A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010514831A (ja) ピペリジンｇｐｃｒアゴニスト
JP2011527332A (ja) ピペリジンｇｐｃｒ作動薬
JP2011500658A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
EP2318399B1 (en) Piperidinyl gpcr agonists
JP2008545008A (ja) Ｇｐｃｒアゴニスト
JP2010514828A (ja) ピペリジンｇｐｃｒアゴニスト
JP2011527334A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
JP2010514829A (ja) ピペリジンｇｐｃｒアゴニスト
JP2009532453A (ja) ヘテロサイクリックｇｐｃｒアゴニスト
JP2011527331A (ja) ピペリジニルｇｐｃｒ作動薬
JP2011527335A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP2008525417A (ja) Ｇタンパク質結合受容体作動薬
HK1157329B (en) Piperidinyl gpcr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130319